Medical Technology

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More

@xconomy.com 4 years ago

Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

@xconomy.com 4 years ago

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

@xconomy.com 5 years ago

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

@xconomy.com 5 years ago

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues

@xconomy.com 5 years ago

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

@xconomy.com 5 years ago

Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More

@xconomy.com 5 years ago

Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

@xconomy.com 5 years ago

Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

@xconomy.com 5 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines